Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2944 participants
INTERVENTIONAL
2009-08-31
2009-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing Numeric Formats for Presenting Data About Treatment Benefits and Harms
NCT00950014
Testing the Effect of a Caution for Drugs Approved on Surrogate Outcomes Alone
NCT00950157
Drug Facts Page or a Short Drug Summary in Helping Patients and Doctors Understand Medical Information
NCT00450931
Patient Profiling and Provider Feedback to Reduce Adverse Drug Events
NCT00013143
FDA "Breakthrough Drugs": A Trial Testing the Effect of Alternative Language on Public Perceptions
NCT02428556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Directive new drug warning
Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.
This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record.
Presentation of information about drug approval and level of warning
Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
Non-directive new drug warning
Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.
This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market.
Presentation of information about drug approval and level of warning
Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
No new drug warning
Survey contains information about when the drug was approved by the FDA (2009) only.
Presentation of information about drug approval and level of warning
Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Presentation of information about drug approval and level of warning
Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Attorney General Consumer & Prescriber Education Grant
OTHER
White River Junction Veterans Affairs Medical Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
White River Junction VAMC
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisa M Schwartz, MD, MS
Role: PRINCIPAL_INVESTIGATOR
White River Junction Veterans Affairs Medical Center
Steven Woloshin, MD, MS
Role: PRINCIPAL_INVESTIGATOR
White River Junction Veterans Affairs Medical Center
References
Explore related publications, articles, or registry entries linked to this study.
Schwartz LM, Woloshin S. Communicating uncertainties about prescription drugs to the public: a national randomized trial. Arch Intern Med. 2011 Sep 12;171(16):1463-8. doi: 10.1001/archinternmed.2011.396.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16784
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.